Intratumoral CD3+CD8+T Cell Ratio Correlated with Overall Survival in Stage IV Cervical Cancer

M. Cai,X. Tan,X. Sun,Y. Ma,H. Tang,J. Ma
DOI: https://doi.org/10.1016/j.ijrobp.2020.07.1648
2020-01-01
Abstract:Survival rates for women with Stage IV cervical cancer are low. The expression of CD3, CD4, and CD8 in tumor tissues is widely accepted to be related to the patient's prognosis to a certain extent. However, the correlation in cervical cancer is unknown. We aimed to assess the expression of CD3, CD4, and CD8 on overall survival (OS) and disease-free survival (PFS) in Stage IV cervical cancer. 157 cervical cancer patients with stage IV (FIGO 2009) were enrolled in this study between 1/2010 and 12/2019. The expressions of CD3, CD4 and CD8 in the tissue samples were detected by immunohistochemistry. The standard for evaluation scale of marks of the situation of dye is below: The staining intensity of immunohistochemistry was divided into 3 levels: negative, weakly positive, strong positive. Most patients received radiotherapy for primary focus and chemotherapy. Outcomes were evaluated via Kaplan-Meier, and associations were examined via Cox proportional hazards modeling. The median follow-up duration was 28 months. The samples were identified and the expression level were defined by professional pathologists. Among these, 64 tissue samples presented with CD3+ CD4+CD8+, 41 samples showed CD3+CD4+CD8-, and 39 samples showed CD3+CD8+CD4-. Compared with CD3+CD8+CD4-, CD3+CD4+CD8- was associated with improved OS (hazard ratio: 0.56; 95% confidence interval, 0.33-0.95; P = 0.023). The median OS rate was 34 months in the CD3+CD8+CD4- group and 20 months in the CD3+CD4+CD8- group. However, the expression of CD3, CD4 and CD8 was not correlated statistically with PFS (hazard ratio: 0.75; 95% confidence interval, 0.47-1.20; P = 0.19). Among CD3+ stage IV cervical cancer patients, the ones with positive expression of CD8 had improved OS. These results show that intratumoral CD3+CD8+ T cell ratio may play a pivotal role in determining the prognosis of patients with stage IV cervical cancer, which we attribute to the activation of adaptive T cell immunity, especially CD8+ T cell immune response.
What problem does this paper attempt to address?